Variable | C N=2842 (69.3%) | P N=391 (9.5%) | Switch C to P N=678 (16.5%) | Switch P to C N=190 (4.6%) |
---|---|---|---|---|
Male gender | 1913 (67.3%) | 348 (89.0%) | 573 (84.5%) | 158 (83.2%) |
Age, years | 68±14 | 56±11 | 56±11 | 56±11 |
STEMI | 1303 (45.8%) | 295 (75.4%) | 472 (69.6%) | 143 (75.3%) |
Hypertension | 1699 (59.8%) | 144 (36.8%) | 286 (42.2%) | 57 (30.0%) |
Hypercholesterolaemia | 1250 (44.0%) | 154 (39.4%) | 295 (43.5%) | 80 (42.1%) |
Current smoking | 780 (27.4%) | 201 (51.4%) | 364 (53.7%) | 106 (55.8%) |
Diabetes | 628 (22.1%) | 46 (11.8%) | 107 (15.8%) | 35 (18.4%) |
Body weight, kg | 75±15 | 80±14 | 82±14 | 81±18 |
Prior MI | 489 (17.2%) | 30 (7.7%) | 97 (14.3%) | 10 (5.3%) |
Prior PCI | 457 (16.1%) | 37 (9.5%) | 108 (15.9%) | 13 (6.8%) |
Prior CABG | 189 (6.7%) | 20 (5.1%) | 28 (4.1%) | 9 (4.7%) |
History of HF | 156 (5.5%) | 2 (0.5%) | 11 (1.6%) | 1 (0.5%) |
History of stroke | 131 (4.6%) | 3 (0.8%) | 6 (0.9%) | 0 (0.0%) |
PAD | 269 (9.5%) | 15 (3.8%) | 31 (4.6%) | 5 (2.6%) |
CKD | 145 (5.1%) | 4 (1.0%) | 11 (1.6%) | 1 (0.5%) |
COPD | 195 (6.9%) | 22 (5.6%) | 37 (5.5%) | 12 (6.3%) |
Admission Killip>2 | 158 (5.8%) | 7 (1.9%) | 14 (2.1%) | 2 (1.1%) |
Admission SBP, mm Hg | 145±29 | 142±27 | 145±26 | 144±28 |
Admission HR, bpm | 80±21 | 77±20 | 77±19 | 78±17 |
Early GRACE score | 147±37 | 127±26 | 125±29 | 126±30 |
Creatinine, mmol/L | 101±107 | 90±57 | 87±25 | 83±24 |
GFR, mL/min | 70±37 | 89±28 | 91±30 | 96±40 |
Admission to centre with on-site cathlab | 1933 (68%) | 345 (88.2%) | 500 (73.7%) | 121 (63.7%) |
Primary PCI | 804 (58.5%) | 253 (84.9%) | 328 (69.5%) | 110 (75.9%) |
Coronary angioplasty | 2060 (72.4%) | 390 (93.0%) | 645 (95.1%) | 176 (92.6%) |
Recurrent MI | 26 (0.9%) | 3 (0.8%) | 14 (2.1%) | 1 (0.5%) |
Stent thrombosis | 8 (0.3%) | 3 (0.8%) | 9 (1.3%) | 1 (0.5%) |
Major bleeding | 14 (0.5%) | 3 (0.8%) | 0 (0.0%) | 1 (0.5%) |
Fatal bleeding | 1 (0.0%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Hb drop of 3–5 g/dL | 226 (8.0%) | 20 (5.1%) | 49 (7.2%) | 17 (8.9%) |
Hb drop≥5 g/dL | 60 (2.1%) | 10 (2.6%) | 6 (0.9%) | 4 (2.1%) |
BARC bleed type 3A | 46 (1.6%) | 4 (1.0%) | 10 (1.5%) | 5 (2.6%) |
BARC bleed type 3B | 70 (2.5%) | 10 (2.6%) | 6 (0.9%) | 4 (2.1%) |
BARC bleed type 3C | 2 (0.1%) | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
Transfusion | 118 (4.2%) | 4 (1.0%) | 3 (0.4%) | 3 (1.6%) |
In-hospital death | 98 (3.4%) | 2 (0.5%) | 2 (0.3%) | 1 (0.5%) |
Combined end point* | 80 (3.9%) | 2 (0.8%) | 5 (1.0%) | 1 (0.8%) |
One-year all-cause mortality | 290 (10.2%) | 5 (1.3%) | 12 (1.8%) | 2 (1.1%) |
*Combined end point=death, stent thrombosis, stroke and/or BARC type ≥3 bleeding.
BARC, Bleeding Academic Research Consortium; C, clopidogrel; CABG, coronary artery bypass graft; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; FAST-MI, French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction; GFR, glomerular filtration rate estimated by the Cockroft-Gault formula; cathlab, catheterisation laboratory; GRACE, Global Registry of Acute Coronary Events; Hb, haemoglobin; HF, heart failure; HR, heart rate; kg, kilograms; MI, myocardial infarction; P, prasugrel; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention; SBP, systolic blood pressure; STEMI, ST segment elevation myocardial infarction.